全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年)
Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2016-2021)
|出版商||Mordor Intelligence LLP||商品編碼||353905|
|全球大腸癌症診斷、治療藥市場 (各診斷、技術、地區) :預測 (2015年∼2020年) Global Colorectal Cancer Diagnostics & Therapeutics Market - Segmented by diagnosis, technology and geography (2016-2021)|
|出版日期: 2016年03月01日||內容資訊: 英文||
The global colorectal cancer diagnostics and therapeutics market is expected to grow at a compound annual growth rate (CAGR) of 1-5% during the forecast period of 2015-2020. The market is valued at USD 14,143 million, as per 2015.
The CRC pipeline is highly robust, with a number of potential drug candidates present across the various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or as second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. Along with these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.
The global colorectal cancer diagnostics and therapeutics market is segmented on the basis of:
Some of the key players of the market are Abbott diagnostics, Alere, Beckman coulter, clinical genomics, Companion DX, EDP Biotech, Epigenomics AG, Exact sciences, Genomic tree, Metabiomics, Oncocyte, Quest Diagnostics, Randox Laboratories, Siemens Healthcare etc.